Revel Pharmaceuticals Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4M
- Investors
-
10
Revel Pharmaceuticals General Information
Description
Developer of therapeutic enzymes designed for degrading molecular damage associated with aging. The company's platform integrates enzyme discovery and engineering capabilities, encompassing design, optimization, and production of repair based catalytic treatments that clear toxic metabolites and protein modifications, enabling healthcare providers and researchers to target a range of age related diseases such as osteoarthritis, kidney disease, cardiovascular disease, skin aging, and complications of diabetes with molecular level repair.
Contact Information
Website
www.revelpharmaceuticals.comCorporate Office
- 2325 3rd Street
- Room 214
- San Francisco, CA 94107
- United States
Corporate Office
- 2325 3rd Street
- Room 214
- San Francisco, CA 94107
- United States
Revel Pharmaceuticals Timeline
Revel Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 30-Sep-2025 | $4M | Completed | Generating Revenue | ||
| 7. Grant | 01-May-2024 | Completed | Generating Revenue | |||
| 6. Grant | 01-Aug-2023 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 17-Mar-2022 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 07-Apr-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 01-Jan-2021 | Cancelled | Generating Revenue | |||
| 2. Seed Round | 07-Jan-2020 | $1.5M | $1.5M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Startup |
Revel Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-2 | ||||||||
| Seed-1 | ||||||||
| Seed | 3,555,472 | $0.000010 | $0.3 | $0.3 | 1x | $0.3 | 6.42% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Revel Pharmaceuticals Signals
Revel Pharmaceuticals Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gaingels | Venture Capital | Minority | ||
| Hyperspeed Ventures | Venture Capital | Minority | ||
| LongGame Ventures | Venture Capital | Minority | ||
| U.S. Department of Health and Human Services | Government | |||
| Formic Ventures | Venture Capital | Minority |
Revel Pharmaceuticals FAQs
-
When was Revel Pharmaceuticals founded?
Revel Pharmaceuticals was founded in 2020.
-
Where is Revel Pharmaceuticals headquartered?
Revel Pharmaceuticals is headquartered in San Francisco, CA.
-
What is the size of Revel Pharmaceuticals?
Revel Pharmaceuticals has 8 total employees.
-
What industry is Revel Pharmaceuticals in?
Revel Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Revel Pharmaceuticals a private or public company?
Revel Pharmaceuticals is a Private company.
-
What is Revel Pharmaceuticals’s current revenue?
The current revenue for Revel Pharmaceuticals is .
-
How much funding has Revel Pharmaceuticals raised over time?
Revel Pharmaceuticals has raised $14.7M.
-
Who are Revel Pharmaceuticals’s investors?
Gaingels, Hyperspeed Ventures, LongGame Ventures, U.S. Department of Health and Human Services, and Formic Ventures are 5 of 10 investors who have invested in Revel Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process